SCHEMBL2004447

SCHEMBL2004447

CC(C)(C)[C@@]1(C)CN(Cc2ccc([N+](=O)[O-])cc2C(F)(F)F)CCN1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 2/20 0.41
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
ATM Q13315 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
GAA P10253 1/20 0.38
NR1H2 P55055 1/20 0.37
AR P10275 1/20 0.37
KIT P10721 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTSB P07858 1/20 0.36
FAAH O00519 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
BRAF P15056 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995977 0.85 NR1H2 (0.55) ALDH1A1KDM4EATMNPSR1TDP1
SCHEMBL377869 0.81 KDM4E (0.53) KCNJ1ALDH1A1KDM4ETDP1HTT
SCHEMBL377528 0.81 KDM4E (0.53) KCNJ1ALDH1A1KDM4ETDP1HTT
SCHEMBL27088090 0.76 NR1H2 (0.43) KCNJ1ALDH1A1KDM4ENPSR1NR1H2
SCHEMBL1420633 0.76 NR1H2 (0.49) KCNJ1ALDH1A1KDM4ENR1H2MEN1
SCHEMBL588829 0.76 NR1H2 (0.62) ALDH1A1KDM4ENR1H2KITSMN1; SMN2
SCHEMBL2849484 0.76 MGLL (0.49) KCNJ1ALDH1A1KDM4EATMNPSR1
SCHEMBL2849487 0.76 MGLL (0.49) KCNJ1ALDH1A1KDM4EATMNPSR1
SCHEMBL3554138 0.75 KDM4E (0.39) KCNJ1ALDH1A1KDM4ENPSR1TDP1
SCHEMBL28291908 0.75 NR1H2 (0.39) KCNJ1ALDH1A1KDM4ENR1H2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964597-B2 Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases GLAXO GROUP LIMITED (GB) 2011-06-21 US disclosed